Stock Ratings / Health Care / PROK / financials

EDIT (38) ALLO (33) AUTL (21) CCCC (28) ⌘ Pro Terminal →

ProKidney Corp. (Class A) (PROK) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.30 -11.90% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.27

ProKidney Corp. (Class A) (PROK) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $444.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PROK Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PROK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, ProKidney Corp. (Class A) (NASDAQ: PROK) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.30 (-11.90% 1D, market cap $444.4M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PROK ranks #608 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PROK compare to EDIT and ALLO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PROK carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EDIT (Editas Medicine Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $450.0M) and ALLO (Allogene Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $431.9M). Among the 5-stock peer group, PROK leads on earnings multiple (N/A) while PROK leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PROK?

▼

Per PROK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001850270), ProKidney Corp. (Class A) generated $0 in revenue, -$69.0M in net income, and -$135.3M in free cash flow against $335.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.27 (-2.33%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PROK)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY PROK SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 47.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.67-16.8% Next Q

Q2 (-2Q)

Grade D$1.39-2.2% Next Q

Q3 (-1Q)

Grade D$1.36-4.4% Next Q

Current

Grade D-$1.30-8.1% Hist 90D α

Trajectory: D (45) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PROK Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PROK currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.66) and Max Pain ($1.37) forces dealer call-delta covering toward $3.29.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PROK• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PROK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How PROK Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-4.1%	-$69.0M	-$135.3M	-45%
FY 2024	$4.00B	52%	-4.6%	-$61.2M	-$155.9M	-45%
FY 2023	$4.00B	52%	-3.8%	-$35.5M	-$90.1M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PROK)

✓Walkthrough of PROK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PROK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.85%🛡️ HOLDING TREND SUPPORT

2026-11-02O $1.52H $1.52L $1.30C $1.30VOL 821.2K

RES: $1.96SUP: $1.30SMA50: $1.66SMA200: $1.81

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PROK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PROK Butterfly Map → + Track PROK →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PROK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PROK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PROK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PROK)

Health Care Rank #608 of 1016 ⚔️ EDIT vs PROK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PROK vs. EDIT, ALLO, AUTL, CCCC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ProKidney Corp. (Class A) (PROK) ranks #608 by composite RQD confidence (37/100, grade D-) and #468 by equity capitalization ($444.4M). Within this direct 5-issuer industry benchmark cohort, PROK leads on earnings valuation at N/A trailing P/E, while PROK leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. EDIT currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with PROK at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PROK ACTIVE ProKidney Corp. (Class A)	D-	37/100	—	—	-35.0%	-11.90%	$444.4M	Benchmark Subject
EDIT Editas Medicine Inc.	D-	38/100	—	—	-35.0%	-8.87%	$450.0M	/edit-vs-prok →
ALLO Allogene Therapeutics Inc.	E	33/100	—	—	-35.0%	-5.60%	$431.9M	/allo-vs-prok →
AUTL Autolus Therapeutics plc	E	21/100	—	-27.8%	-35.0%	-3.80%	$420.5M	/autl-vs-prok →
CCCC C4 Therapeutics Inc.	E	28/100	—	—	-35.0%	+2.12%	$406.0M	/cccc-vs-prok →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001850270

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ProKidney Corp. (Class A) (PROK) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$69.0M, operating cash flow of -$120.1M, and free cash flow of -$135.3M (+13.2% YoY). On the balance sheet, PROK closed FY2025 with $335.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$69.0M	-$120.1M	-$135.3M	$335.6M	—
FY2024 (FY)	2024-12-31	$0	-$61.2M	-$126.4M	-$155.9M	$441.1M	—
FY2023 (FY)	2023-12-31	$0	-$35.5M	-$90.1M	-$90.1M	—	—

3. PROK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PROK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PROK compare to EDIT and ALLO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PROK?

Where is PROK trading relative to its 50-day, 200-day, and 52-week technical levels?

PROK last traded at $1.30 (-11.90% on volume of 1,730,751 shares), positioning the stock -21.69% below its 50-day simple moving average ($1.66) and -28.18% below its 200-day simple moving average ($1.81). Across its 52-week range of $1.29 to $3.13, PROK sits at the 0.5% percentile with a 14-day RSI of 47.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.14 to $1.46).

PROK Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is ProKidney Corp. (Class A) (PROK)?

In FY 2025 (10-K), PROK converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: PROK RQD Cockpit PROK 12M Forecast PROK Earnings & Move PROK Dividends & DRIP PROK Insiders & 13F PROK Whale Options PROK Profit Sankey PROK News & Why

ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PROK — ProKidney Corp. (Class A): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:36:23Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PROK scores 37 out of 100, graded D- and labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 7/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 5/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 10/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5).

Read together, the weakest pillars are the cash engine and the flow signals. A 0% FCF yield and -35% ROIC indicate the business is not currently generating returns on invested capital, so any valuation case must rest on future cash generation rather than present earnings. The balance-sheet pillar is middling: the Altman Z of 2.5 and Debt/Equity of 0.5 are not distressed levels, but a Piotroski F-Score of 1 out of 9 signals very weak financial-health indicators. The flow pillars (5/20 each) suggest limited institutional and insider conviction in the source data. Upside drivers would need to come from a change in the cash-burn trajectory or an external catalyst; the source data does not establish either. Valuation tradeoffs are significant because the company has no positive earnings or cash flow to anchor a multiple. This is an analytical framing, not personalized advice.

Business

Per the profile, ProKidney Corp. (Class A) (PROK) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The profile reports a market capitalization of $0.4B. Per the SEC financials, reported revenue is $0.0M for each of the three listed fiscal years, so the source data does not show a current revenue-generating product or customer base. Not available in source data for how the company makes money or who its customers are.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-165.0M	$-69.0M	N/A	$-135.3M	$108.5M	N/A
FY 2024	$0.0M	$-183.7M	$-61.2M	N/A	$-155.9M	$99.1M	N/A
FY 2023	$0.0M	$-151.5M	$-35.5M	N/A	$-90.1M	N/A	N/A

Per the SEC financials, all three periods show zero revenue, operating losses, and negative free cash flow. Gross, operating, and net margins are each reported as 0% in the market data. ROIC is -35% per the market data. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1 out of 9. Reported cash rose to $108.5M in FY 2025 from $99.1M in FY 2024, while Debt/Equity is 0.5 per the RQD forensic pillar.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the most material items are:

A $200 Million At-the-Market stock offering with Jefferies (TradingView), indicating an equity-issuance pathway that could add shares outstanding.
An analysis piece discussing the Rilparencel mechanism and its role in advanced chronic kidney disease (Seeking Alpha, dated 2026-10-28).
A MarketBeat report noting a 6% stock price decline.
A Globe and Mail piece referencing analysts' insights on ProKidney alongside Biogen and Beam Therapeutics.
A Stock Titan report that a regulatory chief converted shares into 200,000 Class A shares.

Risk watch items from the feed: the at-the-market offering and the reported price decline. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, and no proprietary signals are present. All news items carry a YELLOW light designation in the source.

Open Questions

What is the company's revenue model, given zero reported revenue across all listed periods?
What is the cash runway implied by the $108.5M cash balance against FY 2025 free cash flow of $-135.3M?
What are the terms, pricing, and share-count impact of the $200 Million at-the-market offering?
Why are EPS, P/E, EV/EBITDA, and Debt values absent from the source data?
What is the status and timing of the Rilparencel program referenced in the news feed?

PROK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ProKidney Corp. (Class A) (PROK) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PROK Debate Forum (3) ↓

🟡 MARKET WIRE Simply Wall St • 10h ago

ProKidney (Nasdaq:PROK) - Stock Analysis

Simply Wall St report covering ProKidney Corp. (Class A) (PROK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 13h ago

ProKidney Establishes $200 Million At-the-Market Stock Offering With Jefferies

TradingView report covering ProKidney Corp. (Class A) (PROK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 16h ago

ProKidney Corp. (PROK) Discusses Rilparencel Mechanism and Role in Advanced Chronic Kidney Disease - Slideshow (NASDAQ:PROK) 2026-10-28

Seeking Alpha report covering ProKidney Corp. (Class A) (PROK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 19h ago

ProKidney (NASDAQ:PROK) Stock Price Down 6% - Here's Why

MarketBeat report covering ProKidney Corp. (Class A) (PROK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 22h ago

Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Beam Therapeutics (BEAM) and ProKidney (PROK)

The Globe and Mail report covering ProKidney Corp. (Class A) (PROK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Regulatory chief converts shares at ProKidney (PROK), receiving 200,000 Class A shares.

Stock Titan report covering ProKidney Corp. (Class A) (PROK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Citigroup Has Lowered Expectations for ProKidney (NASDAQ:PROK) Stock Price

MarketBeat report covering ProKidney Corp. (Class A) (PROK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

ProKidney Corp. (PROK) Slides 8.59% to $1.33 as Shares Test Lower Support - Jurik MA

https://www.siam.in/ report covering ProKidney Corp. (Class A) (PROK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PROK Bull vs. Bear Conversation Board — What's Your Call at $1.30?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PROK 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.29 (-12.2%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PROK (D- • RQD 37/100) a Buy at $1.47?

Welcome to the PROK (ProKidney Corp. (Class A)) Roar Pit. Current RQD Composite is 37/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.12 (-23.8%)

Spot @ $1.47

Pump the brakes on PROK — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PROK, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless ProKidney Corp. (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.72 (+17.0%)

Spot @ $1.47

PROK cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PROK, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $1.47 (52-wk range $1.29 - $3.13), any beat on forward guidance forces shorts and underweight funds to chase.